Danish pharmaceutical company, Lundbeck, made two key acquisitions that strengthen its position central nervous system drugs. It acquired LifeHealth Ltd for its stake in Xenazine® (terbenazine) a treatment for a symptom of Huntington’s disease and a Danish biotech, NeuronIcon to gain technologies for the treatment of brain damage.